Technical Analysis for IMVT - Immunovant, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Up |
Historical IMVT trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Crossed Above 20 DMA | Bullish | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 2.45% | |
Bullish Engulfing | Bullish | 3.72% | |
Stochastic Reached Oversold | Weakness | 3.72% | |
Outside Day | Range Expansion | 3.72% | |
Oversold Stochastic | Weakness | 3.72% | |
Down 3 Days in a Row | Weakness | 4.40% | |
20 DMA Resistance | Bearish | 3.11% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 21 hours ago |
Rose Above 20 DMA | about 23 hours ago |
Rose Above 10 DMA | about 23 hours ago |
Rose Above Previous Day's High | about 23 hours ago |
20 DMA Resistance | about 23 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/01/2020
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Eye Immune System Antibodies Autoimmune Diseases Monoclonal Antibody Monoclonal Antibodies Autoimmune Disease Thyroid Anemia Eye Disease Transfusion Medicine Treatment Of Autoimmune Disease Treatment Of Autoimmune Diseases Myasthenia Myasthenia Gravis Acquired Hemolytic Anemia Roivant Sciences Thyroid Eye Disease Treatment Of Myasthenia Gravis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Eye Immune System Antibodies Autoimmune Diseases Monoclonal Antibody Monoclonal Antibodies Autoimmune Disease Thyroid Anemia Eye Disease Transfusion Medicine Treatment Of Autoimmune Disease Treatment Of Autoimmune Diseases Myasthenia Myasthenia Gravis Acquired Hemolytic Anemia Roivant Sciences Thyroid Eye Disease Treatment Of Myasthenia Gravis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 53.75 |
52 Week Low | 11.8 |
Average Volume | 1,444,671 |
200-Day Moving Average | 33.16 |
50-Day Moving Average | 16.46 |
20-Day Moving Average | 15.70 |
10-Day Moving Average | 15.56 |
Average True Range | 0.87 |
ADX | 25.42 |
+DI | 23.70 |
-DI | 28.60 |
Chandelier Exit (Long, 3 ATRs ) | 14.53 |
Chandelier Exit (Short, 3 ATRs ) | 16.73 |
Upper Bollinger Band | 16.63 |
Lower Bollinger Band | 14.76 |
Percent B (%b) | 0.61 |
BandWidth | 11.91 |
MACD Line | -0.61 |
MACD Signal Line | -0.83 |
MACD Histogram | 0.2142 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 17.22 | ||||
Resistance 3 (R3) | 17.19 | 16.72 | 17.00 | ||
Resistance 2 (R2) | 16.72 | 16.38 | 16.74 | 16.93 | |
Resistance 1 (R1) | 16.31 | 16.18 | 16.52 | 16.34 | 16.85 |
Pivot Point | 15.84 | 15.84 | 15.94 | 15.86 | 15.84 |
Support 1 (S1) | 15.43 | 15.50 | 15.64 | 15.46 | 14.95 |
Support 2 (S2) | 14.96 | 15.30 | 14.98 | 14.87 | |
Support 3 (S3) | 14.55 | 14.96 | 14.80 | ||
Support 4 (S4) | 14.58 |